Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC announced the purchase of 1,281,000 ordinary shares for cancellation as part of its share buyback program. This move is part of the second tranche of the program, initially announced on July 31, 2025. The transaction affects the company’s share capital, reducing the number of shares with voting rights to 8,982,490,355. This strategic step is likely to impact shareholder interests and reflects Haleon’s commitment to optimizing its capital structure.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC scores well due to strong financial performance and strategic corporate actions like share buybacks. However, technical analysis indicates potential short-term bearish trends, and valuation suggests the stock is trading at a premium.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. Its product portfolio includes oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health, and therapeutic skin health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 23,461,824
Technical Sentiment Signal: Hold
Current Market Cap: £32.82B
See more data about HLN stock on TipRanks’ Stock Analysis page.